A newly launched off-the-shelf fat-derived filler may provide the long-lasting results associated with fat grafting plus the convenience of other ready-to-use injectables.

Allofill is Biologica Technologies’ first foray into aesthetics. The company has products in the orthopedic space.

Launched in late September, Allofill is a ready-to-use, allograft-derived filler retains the native extracellular matrix (ECM) components of allograft-derived adipose tissue and over time will be remodeled into a patient's own soft tissue.

Using their tissue processing methods, Biologica Technologies has the ability to harvest various growth factors found within allogeneic adipose tissue and bind them to a collagen scaffold. 

The company is now conducting studies looking at how the new filler performs in the mid-face and temple regions. The cost of the new filler will be comparable to some hyaluronic acid-based injectables on the market.

Additional products to follow include an acellular dermal matrix (ADM) and cartilage matrix.